NDAINHALATIONPOWDER
Approved
Dec 2013
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
4/8 — Partial
Drug data last refreshed 2d ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANORO ELLIPTA is a dual long-acting bronchodilator combining umeclidinium (muscarinic antagonist) and vilanterol (beta-2 agonist) delivered via dry powder inhaler for maintenance treatment of chronic obstructive pulmonary disease (COPD). The combination provides 24-hour bronchospasm relief by relaxing airway smooth muscle through two complementary mechanisms. It is indicated for long-term maintenance of airflow obstruction in patients with COPD.
$873MPart D
PeakStable
4.4 years to LOEPeak-stage product with sustained $873M annual spending generating significant commercial opportunity across field sales, account management, and medical affairs roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on ANORO ELLIPTA at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.